JAMIL ALHASSAN: Open Payments
NPI 1932605300 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,183 in 43 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $1,349 · 2025 $2,183
Food & beverage: $2,183
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 9 | $714 |
| Alkermes, Inc. | 6 | $313 |
| Otsuka America Pharmaceutical, Inc. | 6 | $299 |
| Vanda Pharmaceuticals Inc. | 6 | $216 |
| ABBVIE INC. | 4 | $161 |
| Teva Pharmaceuticals USA, Inc. | 3 | $136 |
| E.R. Squibb & Sons, L.L.C. | 1 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $104 |
| Axsome Therapeutics, Inc. | 1 | $95 |
| Braeburn Inc. | 1 | $24 |
Products named: INVEGA SUSTENNA, SPRAVATO, FANAPT, VRAYLAR, VIVITROL, REXULTI, UZEDY, ABILIFY MAINTENA.
Industry payments across AZ — which companies pay providers there.
